Equities analysts expect that Orchard Therapeutics PLC – (NASDAQ:ORTX) will announce earnings per share of ($0.49) for the current quarter, Zacks reports. Two analysts have issued estimates for Orchard Therapeutics’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.56). The firm is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Orchard Therapeutics will report full year earnings of ($2.32) per share for the current year, with EPS estimates ranging from ($2.83) to ($1.81). For the next year, analysts forecast that the business will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.68) to ($1.84). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Orchard Therapeutics.

ORTX has been the subject of several analyst reports. Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of Orchard Therapeutics in a report on Friday, March 22nd. Zacks Investment Research upgraded Orchard Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, March 27th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.40.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legacy Advisors LLC purchased a new stake in shares of Orchard Therapeutics during the 1st quarter valued at $53,000. Norges Bank purchased a new stake in shares of Orchard Therapeutics during the 4th quarter valued at $629,000. FMR LLC purchased a new stake in shares of Orchard Therapeutics during the 4th quarter valued at $321,012,000. Sofinnova Investments Inc. purchased a new stake in shares of Orchard Therapeutics during the 4th quarter valued at $3,502,000. Finally, Millennium Management LLC purchased a new stake in shares of Orchard Therapeutics during the 4th quarter valued at $4,554,000. 56.65% of the stock is owned by institutional investors.

Shares of ORTX opened at $17.79 on Monday. The firm has a market capitalization of $1.53 billion and a price-to-earnings ratio of -1.74. Orchard Therapeutics has a fifty-two week low of $8.65 and a fifty-two week high of $21.64.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Further Reading: What are Institutional Investors?

Get a free copy of the Zacks research report on Orchard Therapeutics (ORTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.